Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia
Pediatric Cardiology · 04.06.2026
DOI: 10.1007/s00246-026-04323-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Cardiology, online erschienen am 04.06.2026. Verfasst von Yuto Sunaga und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan. ysunaga@yamanashi.ac.jp. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Yamanashi.
Abstract (Originalsprache)
For high-dose intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD), individualized selection of second-line therapy according to clinical subgroups could be useful to prevent progression of coronary artery abnormalities. We retrospectively analyzed IVIG-resistant KD patients aged ≥ 1 year treated with additional IVIG ( n = 70) or infliximab (IFX) ( n = 54) by applying clustering approaches. Consistent with previous studies, fever resolved significantly faster in the IFX group (median 72 h) than in the second IVIG group (96 h; p = 0.02). However, the incidence of residual coronary artery abnormalities (Z-score ≥ 2.5) at 30 days, 6 months, and 1 year did not differ significantly between the two treatment groups. In the first clustering approach, which was based on ten baseline laboratory variables, the two identified subgroups were not clearly associated with differential treatment responses. In a secondary clustering analysis using four treatment-associated factors (serum sodium, C-reactive protein, total cholesterol, and HDL cholesterol), the three identified stable subgroups were associated with differential treatment responses. Among the three clusters, Cluster 1 showed a favorable response to second IVIG (resistance rate, 7/36 [19.4%]) but a relatively poor response to IFX (12/28 [42.9%]). In contrast, Clusters 2 and 3, characterized by dyslipidemia with decreased total cholesterol and HDL cholesterol levels, were resistant to second IVIG (7/17 [41.2%] and 8/17 [47.1%], respectively) but relatively sensitive to IFX (0/7 [0%] and 6/19 [31.6%], respectively). These findings suggest that IFX may be an effective second-line therapy for IVIG-resistant KD patients with severe dyslipidemia, whereas additional IVIG may remain beneficial for those without dyslipidemia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan. ysunaga@yamanashi.ac.jp.
- Department of Pediatrics, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.
- Department of Neonatology, Yamanashi Prefectural Central Hospital, Kofu, Yamanashi, Japan.
- Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan.
- Department of Pediatrics, Yamanashi Prefectural Central Hospital, Kofu, Yamanashi, Japan.
- Department of Pediatrics, Yamanashi Kosei Hospital, Yamanashi, Yamanashi, Japan.
Förderung
- University of Yamanashi
Zitieren
APA
Sunaga, Y., Hasebe, Y., Yoshizawa, M., Kono, Y., Koizumi, K., Katsumata, N., Toda, T., Hoshiai, M., Kobayashi, K., Hokibara, S., Oshiro, H., Sawanobori, E., Sano, T., Ohta, M., Tsuruta, M., Nakamura, M., Sato, K., Sato, H., & Inukai, T. (2026). Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia. Pediatric Cardiology. https://doi.org/10.1007/s00246-026-04323-y
Vancouver
Sunaga Y, Hasebe Y, Yoshizawa M, Kono Y, Koizumi K, Katsumata N, et al. Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia. Pediatric Cardiology. 2026. doi:10.1007/s00246-026-04323-y
BibTeX
@article{Sunaga2026,
author = {Sunaga, Yuto and Hasebe, Yohei and Yoshizawa, Masashi and Kono, Yosuke and Koizumi, Keiichi and Katsumata, Nobuyuki and Toda, Takako and Hoshiai, Minako and Kobayashi, Koji and Hokibara, Sho and Oshiro, Hiroko and Sawanobori, Emi and Sano, Tomoaki and Ohta, Masanori and Tsuruta, Makoto and Nakamura, Makoto and Sato, Kazumasa and Sato, Hiroki and Inukai, Takeshi},
title = {Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia},
journal = {Pediatric Cardiology},
year = {2026},
doi = {10.1007/s00246-026-04323-y}
}
EUVIMED